tumor, Chemotherapy induced nausea and vomiting
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: ? Age = 18 years old, ECOG PS score 0-2; ? diagnosed with malignant tumors using histological or cytological methods; ?receiving chemotherapy for the first time; ? Accept moderate emetic risk chemotherapy regimens, including oxaliplatin containing chemotherapy regimens, irinotecan containing chemotherapy regimens, nedaplatin containing chemotherapy regimens, etc; ? Hematology, liver and kidney function, and important organ function indicators meet the requirements of chemotherapy; ? For female patients, the pregnancy test should be negative, and sufficient contraceptive measures should be taken throughout the entire study period; ? Sign informed consent forms.
Exclusion criteria
Exclusion criteria: ? Mental disability or emotional disorders; ? Receive radiotherapy during the trial period; ? Receive the investigational drug 5 days prior to trial admission; ? Nausea and vomiting appeared 24 hours before treatment; ? Currently undergoing anti epileptic treatment; ? Long term hormone users (including those with immune system diseases such as systemic lupus erythematosus, adrenal cortex dysfunction, etc.); ? Taboos for using 5-HT3 RA, dexamethasone, and betamethasone; ? Primary or metastatic central nervous system tumors; ? Pregnant or lactating women; ? The researchers consider that it is not suitable for participants.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The incidence of complete delayed response 24 to 120 hours after chemotherapy;Overall satisfaction of subjects with treatment after 120 hours of chemotherapy;the Functional Living Index-Emesis after 120 hours of chemotherapy;adverse events; | — |
Primary
| Measure | Time frame |
|---|---|
| The incidence of complete acute reactions within the first 24 hours after chemotherapy; | — |
Countries
China
Contacts
The People's hospital of Jianyang City